ACTU · XBRL financial data

Actuate Therapeutics financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ACTU's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	4,373	3,757	3,686*	3,220	2,765	2,178	2,130*	2,565	2,067
General and administrative	1,063	1,636	2,873*	3,145	3,204	3,294	2,559*	3,141	2,840
Total operating expenses	5,435	5,393	6,559*	6,366	5,969	5,472	4,688*	5,706	4,907
Operating income (loss)	(5,435)	(5,393)	(6,559)*	(6,366)	(5,969)	(5,472)	(4,688)*	(5,706)	(4,907)
Interest income	9	81	118*	54	25	70	140*	85	45
Interest expense	5	3	5*	5	5	5	5*	5	5
Income tax expense (benefit)	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(6,572)	(5,971)	(6,446)*	(6,317)	(5,949)	(5,407)	(4,554)*	(5,626)	(4,867)
Earnings per share, basic USD per share	(4.20)	(0.55)	—	(0.32)	(0.30)	(0.25)	(0.19)*	(0.24)	(0.20)
Earnings per share, diluted USD per share	(4.20)	(0.55)	—	(0.32)	(0.30)	(0.25)	(0.19)*	(0.24)	(0.20)
Weighted average shares, basic thousands of shares	1,566	10,773	—	19,498	19,646	21,395	23,500*	23,537	23,872
Weighted average shares, diluted thousands of shares	1,566	10,773	—	19,498	19,646	21,395	23,500*	23,537	23,872

Fiscal quarters (ACTU's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	352	13,523	8,642	3,889	6,493	16,925	13,159	8,134	4,426
Prepaid and other current assets	198	739	566	359	196	519	484	385	322
Total current assets	550	14,263	9,208	4,249	6,689	17,444	13,643	8,519	4,748
Total assets	1,731	14,263	9,318	4,483	6,969	17,714	14,036	8,911	5,199
Accounts payable	5,893	2,330	1,921	2,644	3,171	1,245	1,524	1,201	1,077
Total current liabilities	20,073	8,497	8,803	9,154	9,201	6,373	5,707	4,722	3,805
Total liabilities	21,809	8,904	9,214	9,571	9,623	6,778	6,112	5,127	4,210
Accumulated deficit	(119,963)	(125,934)	(132,380)	(138,697)	(144,646)	(150,054)	(154,608)	(160,233)	(165,100)
Total stockholders' equity	(114,257)	5,359	104	(5,088)	(2,654)	10,936	7,924	3,784	989
Total liabilities and equity	1,731	14,263	9,318	4,483	6,969	17,714	14,036	8,911	5,199
Common shares outstanding (cover page) thousands of shares	19,532	19,532	19,532	19,620	20,745	23,243	23,710	23,926	24,014

Fiscal quarters (ACTU's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6,572)	(5,971)	(6,446)*	(6,317)	(5,949)	(5,407)	(4,554)*	(5,626)	(4,867)
Stock-based compensation	90*	566*	1,192*	1,125	1,579	1,801*	1,542*	1,356	1,341
Net cash from operating activities	(2,674)*	(9,149)*	(4,772)*	(4,619)	(4,174)*	(6,678)*	(3,736)*	(5,017)	(4,405)*
Proceeds from issuing common stock	—	0*	0*	0	2,163*	1,663*	0*	520	732*
Net cash from financing activities	957*	22,321*	(109)*	(133)	6,777*	17,110*	(29)*	(8)	697*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.